| We, Sanyo, boast of a group of innovative-type expertise engineers. The core of our mission is to send out high quality pharmaceutics to the society. To make this mission a success, we focus on R&D and manufacturing by ourselves, which enables us better than otherwise to nurture precise technologies, to better control the entire production process with responsibility, and to make possible speedy delivery of quality products. Now we are making positive efforts to develop technologies for crystallization and reaction. We are making advanced studies by importing updated analyzers. We are also accepting your outsourcing orders for synthesizing. |
|
 |
|
 |
|
| Heat-cycle type, GL - made, good for up to 230°C, to be used for rearrangement reaction and distillation that need high temperature. |
|
 |
 |
 |
| Upper portion of 200L |
|
Lower portion of 200L |
|
 |
|
| 500L(GL) reactor capable of reacting to 1MPa-added pressure. Compared with conventional reaction caldrons, this 500L makes hydrogenation smoother. |
|
|
 |
|
|
|
 |
|
| This is to compound "Carbinol" and the like from Grignard reagents. |
|
|
 |
|
 |
|
| This is to isolate optically active compound by Crystallization method. |
|
|
 |
|
| It is known that some pharmaceutics, while being of same structure, differ in its crystal melting point, density, and thermodynamics stability etc., causing polymorphism. To make our quality uniform, we consider it inevitable to control this polymorphism. Hence we are studying how this polymorphism happens. We have achieved a success in applying our study to actual production level. Not being satisfied with this success yet, we are continuing our efforts to make our study more complete. |
|
 |
|
| This Column Chromatography, 40cm in diameter and 1.5m in height, isolates a target from the mixture. |
|
|
 |
|
|
 |
|
| We control polymorphism by our crystallizing technology. |
|
 |
|
 |
|
 |
| How is solution when hyper-saturated ? |
|
How is crystal when educing starts ? |
|
How is crystal when educing has been well done ? |
|
|
 |
|
[Pharmaceutics we manufacture]
Psychiatric-care group, anti-allergy group, and others.
[Reaction-related technology]
Grignard Reaction, Condensation Reaction of various kind, Reduction Reaction, Optic Dividing, and other anti-polymorphism technologies. |
|
| [Hydrazone reaction] |
|
 |
|
|
| [Thiophene synthesis] |
|
 |
|
|
| [Thione synthesis] |
|
 |
|
|
| [Seven-membered ring synthesis] |
|
 |
|
|
| [Alkylation] |
|
 |
|
|
| [Five-membered ring synthesis] |
|
 |
|
|
Added to the above, we are making continuous efforts every day on the followings :
• Establishment of perfect hygiene system in our API GMP plants. We are committed to seeking continuous improvement in maintaining safe and environmentally sound manufacturing operations.
• Promoting of more outsourcings from our partners and manufacturing (with a written "Privacy Policy" agreement).
We, Sanyo, since its establishment, have been focusing on the pilot production
of generic pharmaceutics (APIs) and have manufactured many outsourcings
from our partners. Based on our excellent technologies thus accumulated
in many years, we shall strive to further educate ourselves and expand
our access into more diverse areas in this rapidly changing world, to
better serve the pharmaceutical companies we are partnering with. |
|
 |
|
